March 30, 2026 Sweden
DNB Carnegie: DIAGNODE-3 interim readout
Maria Karlsson Osipova - analyst at DNB Carnegie, interviews Diamyd Medical CEO Ulf Hannelius and board member Mark Atkinson, and Joshua Vieth, BreakthroughT1D, following the DIAGNODE-3 interim readout.
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.